Union Minister of State for Health

卫生部长国务卿

Anupriya Patel

阿努普里娅·帕特尔

said on Monday 70 per cent of total vaccines sourced by the World Health Organization (WHO) and 14 per cent of generics imported by the US are from India.

周一表示，世界卫生组织（WHO）采购的疫苗总量的70％和美国进口的仿制药的14％来自印度。

She delivered the keynote address at the inaugural session of the Second Policymakers' Forum organised by the Indian Pharmacopoeia Commission (IPC) here. An international delegation of policymakers and drug regulators from 24 countries is participating in the forum.

她在此地由印度药典委员会（IPC）组织的第二届政策制定者论坛开幕式上发表了主题演讲。来自24个国家的国际政策制定者和药品监管机构代表团正参加该论坛。

Aimed at promoting the recognition of the Indian Pharmacopoeia and collaboration in India's initiative for flagship affordable medicines -- the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) -- the Forum is being organised by the IPC under the aegis of the Ministry of Health and Family Welfare in association with the Ministry of External Affairs..

该论坛旨在促进对印度药典的认可，并推动印度旗舰平价药品计划——“总理印度国民药物计划（PMBJP）”的合作，由印度药典委员会（IPC）在卫生与家庭福利部的领导下，与外交部联合举办。

In her keynote address, Patel emphasised India's commitment to ensuring equitable access to quality-assured medicines and stressed the importance of regulatory harmonisation in facilitating global health equity.

在她的主题演讲中，帕特尔强调了印度确保公平获取质量有保证的药品的承诺，并强调了监管协调在促进全球健康公平方面的重要性。

She also highlighted that 'under the visionary leadership of Prime Minister Shri

她还强调说：“在总理Shri的富有远见的领导下

Narendra Modi

纳伦德拉·莫迪

, India has emerged as a global hub for affordable healthcare solutions and continues to deepen its partnerships with nations through knowledge-sharing, capacity-building and health diplomacy'.

印度已成为全球负担得起的医疗保健解决方案的中心，并继续通过知识共享、能力建设和健康外交加深与各国的伙伴关系。

Live Events

现场活动

Underlining the importance of the Jan Aushadi Kendras, Patel said, 'Our Jan Aushadhi Kendras are the shining examples of India's commitment to provide quality and affordable medicines to all our citizens. Jan Aushadhi has been one of the most powerful instruments of bringing down the out-of-pocket expenditure of our citizens.' .

帕特尔在强调简奥萨迪中心的重要性时说：“我们的简奥沙迪中心是印度致力于为所有公民提供高质量且价格合理的药品的光辉典范。简奥沙迪一直是降低我国公民自费支出的最有力工具之一。”

Highlighting India's strides made in the direction of providing vaccines, Patel said India continues to be a leading supplier of vaccines. 'As much as 70 per cent of WHO's total vaccines are sourced from India,' she said.

帕特尔强调了印度在提供疫苗方面取得的进展，称印度仍然是领先的疫苗供应商。她说：“世界卫生组织总疫苗量的70%来自印度。”

She said during the COVID-19 pandemic, India started the 'Vaccine Maitri' initiative and supplied vaccines to more than 100 friendly countries, which depicts India's deep sense of responsibility towards global health and its intention of helping friendly countries in times of distress.

她说，在新冠疫情大流行期间，印度启动了“疫苗友谊”倡议，并向100多个友好国家提供了疫苗，这描绘了印度对全球健康有着深刻的责任感，并有意在困难时期帮助友好国家。

Patel said, 'India continues to be a leader in drug manufacturing, especially when it comes to generic medicines. 14 per cent of generics imported by the US come from India while India also has the maximum number of

帕特尔说：“印度仍然是制药业的领头羊，尤其是在仿制药方面。美国进口的仿制药中有14%来自印度，而且印度也拥有最多的[仿制药]。”

US FDA

美国食品药品监督管理局

(Food and Drug Administration) recognized drug manufacturing plants.'

（食品和药物管理局）认可的药品制造工厂。

She further underlined that '70% of our generics are exported to the highly regulated

她进一步强调：“我们70%的仿制药出口到监管严格的市场。

markets

市场

and our pharmacopeial regulations are regularly visited to meet the global benchmarks'.

我们的药典规定定期更新，以符合全球标准。

Patel said, 'We have retained the WHO's Global Benchmarking Tool (GBT) framework, Maturity Level 3 (ML3) status which reflects the robustness of India's regulatory framework. Presently, 15 countries in the world recognise Indian Pharmacopeia as a book of standards for drugs, Cuba recently becoming the 15th country to recognise the Indian Pharmacopeia.' .

帕特尔说：“我们保留了世界卫生组织的全球基准工具（GBT）框架，成熟度3级（ML3）地位，这反映了印度监管框架的稳健性。目前，世界上有15个国家承认印度药典为药品的标准参考书，古巴最近成为第15个承认印度药典的国家。”

She said it is not just a regulatory step but a move towards bringing more alignment in the quality standards, expanding access to safe and effective drugs and making

她说，这不仅是监管方面的一个步骤，而且是使质量标准更加一致、扩大安全有效药物的获取渠道以及制作的举措。

trade

贸易

in pharmaceuticals smoother than ever before.

在制药方面比以往任何时候都更加顺畅。

Patel reaffirmed that 'we are committed to helping our partner countries by way of communicating and planning' and 'hope to continue to work together to advance the regulatory collaboration and promote the recognition of the pharmacopeial standards so that we can strive fast towards the shared goal of 'Health for All''..

帕特尔重申：“我们致力于通过沟通与规划来帮助我们的伙伴国家”，并“希望继续共同努力，推动监管合作，促进药典标准的认可，从而快速朝着‘全民健康’的共同目标迈进。”

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)